NUTROPIN RECOMBINANT HUMAN GROWTH HORMONE IN POST RENAL TRANSPLANTATION

NUTROPIN 重组人类生长激素在肾移植后的应用

• 批准号: 6263654
• 负责人: JOSEPH T FLYNN
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263654
• 关键词: child (0-11); clinical research; drug adverse effect; hormone therapy; human subject; human therapy evaluation; kidney transplantation; pediatric pharmacology; postoperative state; recombinant proteins; somatotropin

Poor growth in children with renal failure (CRF) may not be corrected with renal transplantation. Recombinant human growth hormone (rhGH), now in use to treat children with CRF pre-transplantation, may be effective post-transplantation as well, but may cause unique problems such as chronic rejection. This study is intended to study the efficacy and safety of rhGH treatment in this population.

肾功能衰竭（CRF）儿童的生长不良可能无法通过肾移植得到纠正。 重组人生长激素（rhGH），目前用于治疗儿童CRF移植前，可能是有效的移植后，以及，但可能会导致独特的问题，如慢性排斥反应。 本研究旨在研究rhGH治疗在该人群中的疗效和安全性。